Biotech company recovers from failed phase II trial – shows efficacy in cochlear implantation
French company Sensorion failed a mid-stage trial of a potential medical treatment for hearing loss last year, but new data now shows that there may be a way forward for the candidate after all.
French biotech company Sensorion has renewed hope that its potential drug hope called SENS-401 (arazasetron) may have a future after all.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Sensorion initiates study of hearing loss therapy candidate
For subscribers
